Event Details


April 27, 2017 08:00 AM

Members of RedHill’s executive team will be joined by key opinion leaders who will discuss BEKINDA®, its indications, the current treatment landscape, potential markets and the ongoing Phase III and II studies for acute gastroenteritis and IBS-D, respectively. A question and answer panel will be held following the presentations.

A live webcast of the event, including the slide presentation, will be available vie the below link. Please access the webcast at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. A replay of the webcast will be available via the below link for a period of 30 days.

Featured Key Opinion Leaders:

Robert A. Silverman, MD, MS
Lead Investigator, BEKINDA® Phase III Study
Emergency Medicine specialist at the Hofstra North Shore-LIJ Medical Center, Associate Professor at the Hofstra North Shore-LIJ School of Medicine in NY
M. Scott Harris, MD, MS, FACP, AGAF
Consultant to RedHill Biopharma
Member of the Executive Board of the Center for Diagnostics and Therapeutics of the American Gastroenterological Association, Professor of Clinical Pharmacology and Physiology at Georgetown University School, Principal, Middleburg Consultants
Jerry Rosenblatt, PhD
RedHill Biopharma Advisory Board
Managing Partner, Foster Rosenblatt